SECTION 1 - IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

Contact information

General

Fluidigm Corporation
2 Tower Place, Suite 2000, South San Francisco, CA 94080
Main (U.S.): +1 (650) 266-6000
E-mail: techsupport@fluidigm.com

Emergency telephone number

+ (650) 266-6100 (outside US)
+ (866) 358-4354 (toll free)

Product identifier

Cisplatin Conjugated Proteins with Preservatives

Synonyms

None identified

Trade names

None identified

Chemical family

Mixture - contains a polypeptide.

Relevant identified uses of the substance or mixture and uses advised against

For Research Use Only.

Note

This SDS is written to address potential worker health and safety issues associated with the handling of the formulated product/mixture. Workers manufacturing this product/mixture should consult the SDS of each hazardous ingredient for hazard information and handling recommendations.

SECTION 2 - HAZARDS IDENTIFICATION

Classification of the substance or mixture

The classification and labeling listed below is for bulk formulation.

Globally Harmonized System [GHS]

Not classified

Label elements

GHS hazard pictogram

None required

GHS signal word

None required

GHS hazard statements

None required

GHS precautionary statements

None required

Other hazards

Cisplatin conjugated protein with preservatives is an antibody-based mixture. In a workplace setting, the likelihood of systemic effects following an accidental ingestion is low, due to the rapid breakdown of proteins in the digestive system. Based on the large molecular weight of proteins, systemic absorption following inhalation or dermal contact is anticipated to be low. The mixture contains bovine serum albumin, which has been associated with occupational sensitization.

Note

This mixture does not meet criteria for classification under GHS as implemented by Regulation EC No 1272/2008 (EU CLP), WHMIS 2015 (Health Canada), and Hazard Communication Standard No. 1910.1200 (US OSHA).
SECTION 3 - COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS #</th>
<th>EINECS/ELINCS#</th>
<th>Amount</th>
<th>GHS Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>N/A</td>
<td>N/A</td>
<td>&lt;0.1%</td>
<td>Not classified</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>15663-27-1</td>
<td>239-733-8</td>
<td>&lt;0.01%</td>
<td>ATO2: H300; STOT-S1: H370; STOT-S3: H335; STOT-R1: H372; RT1A: H360FD; GCM1B: H340; Carc1B: H350; SC1: H314; EC1: H318</td>
</tr>
<tr>
<td>Bovine serum albumin</td>
<td>9048-46-8</td>
<td>N/A</td>
<td>0.1 – 1.0%</td>
<td>RSS1:H317; RS1:H334</td>
</tr>
</tbody>
</table>

**Note**
The primary ingredient of this mixture is sterile water (~98%). The substance listed above is not classified but is listed because it is the key component and its toxicologic properties have not yet been fully characterized. The remaining components are not hazardous and/or present at amounts below reportable limits. Amounts are listed as ranges; the exact percentage of composition is withheld as a trade secret. See Section 16 for full text of GHS classifications.

SECTION 4 - FIRST AID MEASURES

**Immediate Medical Attention Needed**

No. If exposed or concerned: Get medical advice/attention.

**Eye Contact**

If easy to do, remove contact lenses, if worn. Immediately flush eyes with copious quantities of water for at least 15 minutes. If irritation occurs or persists, notify medical personnel and supervisor.

**Skin Contact**

Wash exposed area with soap and water and remove contaminated clothing/shoes. If irritation occurs or persists, notify medical personnel and supervisor.

**Inhalation**

Immediately move exposed subject to fresh air. If not breathing, give artificial respiration. If breathing is labored, administer oxygen. Immediately notify medical personnel and supervisor.

**Ingestion**

Do not induce vomiting unless directed by medical personnel. Do not give anything to drink unless directed by medical personnel. Never give anything by mouth to an unconscious person. Notify medical personnel and supervisor.

**Protection of first aid responders**

See Section 8 for Exposure Controls/Personal Protection recommendations.

**Most important symptoms and effects, both acute and delayed**

See Sections 2 and 11.

**Indication of immediate medical attention and special treatment needed, if necessary**

Medical conditions aggravated by exposure: None known or reported. Treat symptomatically and supportively.
SAFETY DATA SHEET

Product Identifier: Cisplatin Conjugated Proteins with Preservatives
Catalog ID numbers: Cat# 319XXX & TIS-00001
SDS ID: SDS-00025 Rev 02

SECTION 5 - FIREFIGHTING MEASURES

**Extinguishing media**
Use water spray (fog), foam, dry powder, or carbon dioxide, as appropriate for surrounding fire and materials.

**Specific hazards arising from the substance or mixture**
No information identified. May emit carbon monoxide, carbon dioxide, oxides of nitrogen and sulfur, and other cadmium-, chlorine-, phosphorus-, sulfur- and sodium-containing compounds.

**Flammability/Explosivity**
No explosivity data identified. As product is an aqueous solution, it is not expected to be flammable.

**Advice for firefighters**
Wear full protective clothing and a self-contained breathing apparatus with a full facepiece operated in the pressure demand or other positive pressure mode. Decontaminate all equipment after use.

SECTION 6 - ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**
If product is released or spilled, take proper precautions to minimize exposure by using appropriate personal protective equipment (see Section 8). Area should be adequately ventilated. Do not breathe vapors/mist/spray.

**Environmental precautions**
Do not empty into drains. Avoid release to the environment.

**Methods and material for containment and cleaning up**
DO NOT CAUSE MATERIAL TO BECOME AIRBORNE. For small spills, soak up material with absorbent, e.g., paper towels. For large spills, cordon off spill area and minimize the spreading of spilled material. Soak up material with absorbent. Collect spilled material, absorbent, and rinse water into suitable containers for proper disposal in accordance with applicable waste disposal regulations (see Section 13). Decontaminate the area twice with an appropriate solvent (see Section 9).

**Reference to other sections**
See Sections 8 and 13 for more information.

SECTION 7 - HANDLING AND STORAGE

**Precautions for safe handling**
Follow recommendations for handling pharmaceutical agents (i.e., use of engineering controls and/or other personal protective equipment if needed). Avoid contact with eyes, skin and other mucous membranes. Wash thoroughly after handling. Avoid breathing vapor/mist/spray.

**Conditions for safe storage including any incompatibilities**
Store at 2-8°C in tightly closed container. Avoid strong oxidizers. Store in sealed containers that are appropriately labeled.

**Specific end use(s)**
No information identified.

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

**Note**
Wash hands, face and other potentially exposed areas immediately in the event of physical contact.

**Control Parameters/Occupational Exposure Limit Values**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Issuer</th>
<th>Type</th>
<th>OEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>ACGIH</td>
<td>TLV</td>
<td>2 µg/m³</td>
</tr>
</tbody>
</table>
SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

### Exposure/Engineering controls

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Control</th>
<th>Concentration (µg/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSHA PEL</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Belgium, Hungary, New Zealand TWA</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Japan OEL</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Switzerland MAK</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>United Kingdom TWA</td>
<td></td>
<td>20</td>
</tr>
</tbody>
</table>

Bovine serum albumin

---

**Exposure/Engineering controls**

None required for normal handling of packaged product. If handling bulk product:

- Selection and use of containment devices and personal protective equipment should be based on a risk assessment of exposure potential. If vials are crushed or broken, or if handling bulk formulation: Utilize closed and sealed systems whenever possible. Solutions used for procedures where aerosolization may occur (e.g., pipetting, spraying, pumping, open transfers,) must be handled using a control device such as a ventilated enclosure. Control the potential for spills and leaks by securing all connections. Use clean-in-place systems.

---

**Respiratory protection**

None required for normal handling of packaged product. If handling bulk formulation: Choice of respiratory protection should be appropriate to the task and the level of existing engineering controls.

---

**Hand protection**

None required for normal handling of packaged product. If handling bulk formulation: Wear disposable nitrile or other impervious gloves. Double gloves should be worn for direct handling of solutions. When the material is diluted in an organic solvent, wear gloves that provide protection against the solvent.

---

**Skin protection**

None required for normal handling of packaged product. If handling bulk formulation: Wear disposable outergarment appropriate to the task, booties, two pairs of gloves and safety glasses with side shields. Employees must be trained in proper gowning and degowning practices. An anteroom or transition area is recommended for gowning and degowning.

---

**Eye/face protection**

None required for normal handling of packaged product. If handling bulk formulation: Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary. Base the choice of protection on the job activity and potential for contact with eyes or face. An emergency eye wash station should be available.

---

**Environmental Exposure Controls**

Avoid release to the environment and operate within closed systems wherever practicable. Air and liquid emissions should be directed to appropriate pollution control devices. In case of spill, do not release to drains. Implement appropriate and effective emergency response procedures to prevent release or spread of contamination and to prevent inadvertent contact by personnel.

---

**Other protective measures**

Wash hands in the event of contact with product, especially before eating, drinking or smoking. Protective equipment is not to be worn outside the work area (e.g., in common areas or out-of-doors).
SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Aqueous solution.</td>
</tr>
<tr>
<td>Color</td>
<td>Clear.</td>
</tr>
<tr>
<td>Odor</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Odor threshold</td>
<td>No information identified.</td>
</tr>
<tr>
<td>pH</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Flash point</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Upper/lower flammability or explosive limits</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Vapor density</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Relative density</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Water solubility</td>
<td>Soluble.</td>
</tr>
<tr>
<td>Solvent solubility</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Partition coefficient (n-octanol/water)</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>No information identified.</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>No information identified.</td>
</tr>
</tbody>
</table>

Other information

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular formula</td>
<td>Not applicable (Mixture)</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>Not applicable (Mixture)</td>
</tr>
</tbody>
</table>
SECTION 10 - STABILITY AND REACTIVITY

Reactivity
No information identified.

Chemical stability
No information identified.

Possibility of hazardous reactions
No information identified.

Conditions to avoid
No information identified.

Incompatible materials
No information identified.

Hazardous decomposition products
No information identified.

SECTION 11 - TOXICOLOGICAL INFORMATION

Note
No data for this product/mixture were identified. The following data describe the individual ingredients where applicable.

Information on toxicological effects

Route of entry
Large proteins are unlikely to be absorbed through inhalation, skin contact, or ingestion.

Acute toxicity

<table>
<thead>
<tr>
<th>Compound</th>
<th>Type</th>
<th>Route</th>
<th>Species</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisplatin</td>
<td>LD50</td>
<td>Oral</td>
<td>Rat</td>
<td>14.5 mg/kg</td>
</tr>
<tr>
<td></td>
<td>LD50</td>
<td>Oral</td>
<td>Mouse</td>
<td>32.7 mg/kg</td>
</tr>
<tr>
<td></td>
<td>LD50</td>
<td>Intravenous (IV)</td>
<td>Rat</td>
<td>8 mg/kg</td>
</tr>
<tr>
<td></td>
<td>LD50</td>
<td>Intravenous (IV)</td>
<td>Mouse</td>
<td>11 mg/kg</td>
</tr>
<tr>
<td></td>
<td>LC50</td>
<td>Inhalation</td>
<td>Rat</td>
<td>40250 ppm</td>
</tr>
</tbody>
</table>

Bovine serum albumin

Irritation/Corrosion
No studies identified. Cisplatin can cause eye, skin and/or respiratory tract irritation.

Sensitization
No studies identified.

STOT-single exposure
No studies identified. In rats, single intraperitoneal (IP) injections up to 12.2 mg/kg cisplatin caused leukopenia (characterized by decreases in neutrophils, lymphocytes, and platelets) and bone marrow depression, generalized lymphoid depletion, and intestinal/renal tubular injury, which were most severe 2-4 days post-injection. Similar target organ effects were noted in dogs following single IV doses of 2.5 mg/kg or 5 consecutives intravenous (IV) doses of 0.75 mg/kg/day. Heart effects and sperm degeneration were also seen in monkeys following acute exposure.

STOT-repeated exposure/Repeat-dose toxicity
No studies identified.

Reproductive toxicity
No studies identified. Similar adverse effects on spermatogenesis seen in humans were noted in monkeys administered cisplatin (additional details not provided).
SECTION 11 - TOXICOLOGICAL INFORMATION

Developmental toxicity

No studies identified. In rats, IP doses of cisplatin ≥0.25 mg/kg/day before mating through gestation increased the number of resorptions and decreased the post-natal viability and exploratory behavior of surviving offspring; doses of 0.5 mg/kg/day caused embryolethality and growth retardation.

In rabbits, embryolethality was noted at IP doses >0.125 mg/kg/day, but no teratogenic effects were seen at doses up to 0.5 mg/kg/day.

In mice, IP doses of 10 mg/day administered during organogenesis led to retarded growth and bone formation but caused no major malformations. A single IP dose of ³ 3 mg/kg of cisplatin on day 8 of pregnancy was fetal to ~30% of fetuses. Surviving offspring showed growth retardation and had a number of minor skeletal abnormalities.

Genotoxicity

No studies identified. Cisplatin was mutagenic in bacteria and produced chromosomal aberrations, micronuclei, and sister chromatid exchanges (SCEs) in cultured animal and human cells. It also induced SCEs in vivo in rodents but did not cause in vivo dominant lethal mutations in mice.

Carcinogenicity

Weekly IP injections of a 0.85% cisplatin solution in mice (delivering cisplatin doses equivalent to 1.62 mg/kg) for 16 weeks significantly increased lung adenomas; skin papillomas were increased when cisplatin was co-administered with croton oil as a promoter twice weekly for 52 weeks. In two rat studies, multiple IP injections (3 times 1 mg/kg/week for 3 weeks) induced leukemia. Overall, cisplatin was carcinogenic to rodents at low, occupationally relevant doses. Cisplatin is also listed as a carcinogen by OSHA, IARC (Group 2A - "Probably carcinogenic to humans"), and NTP ("Reasonably anticipated to be a human carcinogen").

Aspiration hazard

No data available.

Human health data

See “Section 2 - Other Hazards”

SECTION 12 - ECOLOGICAL INFORMATION

Toxicity

<table>
<thead>
<tr>
<th>Compound</th>
<th>Type</th>
<th>Species</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>LC₅₀ (96 h)</td>
<td>Fish</td>
<td>34 g/L</td>
</tr>
<tr>
<td>Bovine serum albumin</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

Persistence and Degradability

Polypeptides are expected to degrade rapidly when released into the environment.

Bioaccumulative potential

No data available.

Mobility in soil

No data available.

Results of PBT and vPvB assessment

Not performed.

Other adverse effects

No data available.

Note

No special precautions are necessary.

SECTION 13 - DISPOSAL CONSIDERATIONS

Waste treatment methods

Dispose of wastes in accordance to prescribed federal, state, and local guidelines, e.g., appropriately permitted chemical waste incinerator. Do not send down the drain or flush down the toilet. All wastes containing the material should be properly labeled. Rinse waters resulting from spill cleanups should be discharged in an environmentally safe manner, e.g., appropriately permitted municipal or on-site wastewater treatment facility.
SECTION 14 - TRANSPORT INFORMATION

Transport  
Based on the available data, this product/mixture is not regulated as a hazardous material/dangerous good under EU ADR/RID, US DOT, Canada TDG, IATA, or IMDG.

UN number  
None assigned.

UN proper shipping Name  
None assigned.

Transport hazard classes and packing group  
None assigned.

Environmental hazards  
This product/mixture is not regulated as an environmental hazard or a marine pollutant.

Special precautions for users  
Avoid release to the environment.

Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code  
Not applicable.

SECTION 15 - REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture  
This SDS generally complies with the requirements listed under current guidelines in the US, EU and Canada. Consult your local or regional authorities for more information.

Chemical safety assessment  
Not conducted.

TSCA status  
Not listed.

SARA section 313  
Not listed.

California proposition 65  
Not listed.

Additional information  
No other information identified.

SECTION 16 - OTHER INFORMATION

Full text of H phrases and GHS classifications  
Not applicable.

Sources of data  
Information from published literature and internal company data.
### Abbreviations

ACGIH - American Conference of Governmental Industrial Hygienists; ADR/RID - European Agreement Concerning the International Carriage of Dangerous Goods by Road/Rail; AIHA - American Industrial Hygiene Association; CAS# - Chemical Abstract Services Number; CLP - Classification, Labelling, and Packaging of Substances and Mixtures; DOT - Department of Transportation; EINECS - European Inventory of New and Existing Chemical Substances; ELINCS - European List of Notified Chemical Substances; EU - European Union; GHS - Globally Harmonized System of Classification and Labeling of Chemicals; IARC - International Agency for Research on Cancer; IDLH - Immediately Dangerous to Life or Health; IATA - International Air Transport Association; IMDG - International Maritime Dangerous Goods; NIOSH - The National Institute for Occupational Safety and Health; NTP - National Toxicology Program; OEL - Occupational Exposure Limit; OSHA - Occupational Safety and Health Administration; PBT - Persistent, Bioaccumulative, and Toxic; SARA - Superfund Amendments and Reauthorization Act; STOT - Specific Target Organ Toxicity; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Issue Date

April 2021

### Revisions

Revision 02: CHG-003852

Summary of revision: Section 3 – updated ingredient amounts

### Disclaimer

The information and recommendations in this safety data sheet are, to the best of Supplier’s knowledge, accurate as of the date of issue. Supplier gives no warranty whatsoever, including the warranties of merchantability or of fitness for a particular purpose. Any product purchased is sold on the assumption the purchaser shall determine the quality and suitability of the product. Supplier expressly disclaims any and all liability for incidental, consequential or any other damages arising out of the use or misuse of this product. No information provided shall be deemed to be a recommendation to use any product in conflict with any existing patent rights. Read the Safety Data Sheet before handling product. For Research Use Only. Not for use in diagnostic procedures.